Potential QTc-Prolonging Agents

All categories
DBCAT002691Pharmacologic class

Agents associated with a possible risk of QTc prolongation. A DrugBank category of 197 drugs. 160 of them are approved.

Part of
QTc Prolonging Agents
Also known as
Agents associated with a known or possible risk of QTc prolongation · Intermediate Risk and Risk Modifying QT Prolonging Agents · Intermediate Risk and Risk Modifying QT-Prolonging Agents · Intermediate Risk and Risk Modifying QTc Prolonging Agents · Intermediate Risk and Risk Modifying QTc-Prolonging Agents
Drugs

and 172 more with a free account

What you can answer from here — as of December 10, 2018

197DrugsEach linked to its full drug card
Sign in
366Drug targetsEvery drug–target pair in the class, with bond type
Sign in
71,689Marketed productsAcross the regions we cover, with dosage forms and routes
Sign in
32Routes of administrationHow the drugs in this class are given
Sign in

Which targets do Potential QTc-Prolonging Agents share, and which companies have late-stage candidates in this class?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In